Pluristem (PSTI) Q1/11 Results
Q1/11 net loss of $2.61M or $0.07 per share
PSTI had no revenues while R&D net of participation of the OCS (government re-imbursement) and other grants was $1.54M. This increase is attributed to the increase in stock-based compensation expenses, salaries and lab materials expenses due to the increase in the R&D activity. G&A expense was $1.15M which increased due to an increase in stock based compensation expenses. Financial income was $86K. As of Q1/11, total current assets were $45.6M and total current liabilities were $1.9M. PSTI finances operations from existing cash, funds from grants from the OCS.
- Cash and cash equivalents as of 3/31/11 was $44.86M.
Related Posts
Categories: NASDAQ: PSTI, Q1/11 Results, Stem Cell Research
